Le Lézard
Classified in: Health, Science and technology
Subjects: PER, PET, ANW

Sentrxtm Animal Care, Inc. Announces Formation of Their Ophthalmology Scientific and Medical Advisory Board


SALT LAKE CITY, Jan. 11, 2022 /PRNewswire/ -- Sentrx, an animal health company that transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals, today announced the formation of a US-based Ophthalmology Scientific and Medical Advisory Board (OSMAB) comprised of veterinary and scientific leaders in ophthalmology and clinical trial design. The board will be chaired by Chief Scientific Officer, Sarah Atzet, Ph.D. and will work closely with management to advance the company's clinical pipeline development in the US and the utility of its platform BioHAncetm technology, a patented molecular matrix of cross-linked hyaluronic acid (HA).

"We've assembled a board of prestigious scientific and medical thought leaders to provide Sentrx with relevant and informed counsel in the months and years ahead, as we continue our research and application efforts and development of disruptive innovation in the veterinary ophthalmology space," said CEO of Sentrx Animal Care Brian Segebrecht. "Each member brings unique experience in clinical trial design, antiviral modeling, surgical application and overall industry expertise. The board will help ensure we develop and manufacture products that deliver meaningful innovation to the veterinary ophthalmology space."

The members of the Sentrx OSMAB are:

Sarah Atzet, Ph. D.
David Maggs, BVSc (hons), DACVO
Patricia E. Mundy, VetMB MRCVS MA (hons.) DACVO ML (Penn Law)
David Wilkie, DVM, MS, DACVO
D.J Haeussler, DVM, MS, DACVO
Kate Myrna, DVM, MS, DACVO

Full bios: www.sentrxanimalcare.com/OSMAB

Related Information

About Sentrxtm Animal Care, Inc.
Sentrx is a Salt Lake City-based animal health company that was founded on exclusive, worldwide rights to BioHAncetm technology. This patented and proprietary technology uses advanced bioengineering to create a molecular matrix of crosslinked hyaluronic acid (HA) that produces a cellular scaffolding with unique physical and chemical properties. Sentrx transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals. Sentrx develops and manufactures veterinary ophthalmic and wound care products for companion animals.

To learn more, visit our website at sentrxanimalcare.com.

Mason Williams, Chief Commercial Officer
Sentrxtm Animal Care, Inc.                                                         
(801) 583-2050
[email protected]
570 West 1700 South, Ste 1400
Salt Lake City, UT, 84115

SOURCE Sentrx


These press releases may also interest you

at 17:56
Canadian Cancer Society commends tobacco tax and e-cigarette tax increases in federal budget
The Canadian Cancer Society commends the increases in taxes on tobacco and e-cigarettes in today's federal budget.  The budget increases tobacco taxes by $4.00 per carton of 200 cigarettes effective at midnight, and increases e-cigarette taxes by 12%...

at 17:45
Alvotech and Teva Announce U.S. FDA Approval of SELARSDItm (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
Alvotech and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to...

at 17:31
Global Dental Lasers Market to Witness Upsurge in Growth at a CAGR of ~5% by 2030 | DelveInsight
The rise in demand for dental lasers is mainly driven by the growing occurrence of dental issues like bleeding or inflamed gums, tooth decay, and root infections. Furthermore, advancements in dental technology play a significant role in fostering...

at 17:26
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
Amgen today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American...

at 17:05
Antibe Announces TSX Delisting Review
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Toronto Stock Exchange ("TSX") is reviewing the eligibility for continued listing on the TSX of the securities of the Company. The TSX has identified the Company's financial...

at 16:30
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
Viatris Inc.  will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the...

More news about Health...


News published on and distributed by: